UNSPSC 51385804: Meloxicam

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H13N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VG2QF83CGL, chemically known as 4-hydroxy-2-methyl-n-(5-methyl-2-thiazoyl)-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxide but generally known as meloxicam, which bears US NIH Compound Identifier 5281106. European Medicines Agency schedules Meloxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08726MIG.

UNSPSC 51385804 Meloxicam is a Commodity code designating a single pharmaceutical product line, but state and local procurement activity under this code does not center on meloxicam itself. Instead, recent opportunities posted under the code reflect broader pharmaceutical procurement activity including naloxone, generic multi-source drugs, and over-the-counter products supplied through cooperative purchasing vehicles and direct-to-manufacturer programs. State and local governments buying under this code span county health departments, state health and human services agencies, and multistate purchasing cooperatives; issuing bodies include Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which extends to participating jurisdictions in multiple states including Oregon.

Activity concentrates in Florida and the upper Midwest, with Texas emerging as a market for pharmacy benefit innovation. The Seminole County, Florida IFB S1070000015802, posted June 30, 2026, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: due date is inconsistent with posting date in source), requiring quarterly deliveries and electronic bidding through the county's e-Procurement Portal. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 on January 20, 2026, with a March 26, 2026 response deadline, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with awards effective July 1, 2026 and a two-year initial term; the RFP weighted price competitiveness at 75 percent and required cGMP and Drug Supply Chain Security Act compliance. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, reflecting state interest in alternative contracting models outside traditional pharmacy benefit managers and group purchasing organizations.